The dual nature of specific immunological activity of tumor-derived gp96 preparations

Journal of Experimental Medicine

Volumn 189, Issue 9, 1999, Pages 1437-1442

  Chandawarkar, Rajiv Y ^a,b   Wagh, Mihir S ^a   Srivastava, Pramod K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b AKRON GENERAL MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Downregulation; Heat shock protein; Intradermal; Suppressive T cell

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HEAT SHOCK PROTEIN;

ADOPTIVE TRANSFER; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; DOWN REGULATION; FEMALE; HEAT SHOCK; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOWN-REGULATION; FEMALE; IMMUNIZATION; MICE; MICE, INBRED BALB C;

EID: 0345299172     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.9.1437     Document Type: Article

References (24)

1. Srivastava, P.K., and M.R. Das. 1984. Serologically unique surface antigen of a rat hepatoma is also its tumor-associated transplantation antigen. Int. J. Cancer. 33:417-422.
2. Srivastava, P.K., A.B. DeLeo, and L.J. Old. 1986. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. USA. 83:3407-3411.
3. Palladino, M.A., P.K. Srivastava, H.F. Oettgen, and A.B. DeLeo. 1987. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. I. Detection by a cloned cytotoxic T cell line. Cancer Res. 47:5074-5079.
4. Udono, H., and P.K. Srivastava. 1994. Relative immunogenicities of heat shock proteins gp96, hsp90 and hsp70 against chemically induced tumors. J. Immunol. 152:5398-5403.
5. + T cells in vivo. Proc. Natl. Acad. Sci. USA. 91:3077-3081.
6. Feldweg, A.F., and P.K. Srivastava. 1995. Molecular heterogeneity of the tumor rejection antigen/heat shock protein gp96. Int. J. Cancer. 63:310-314.
7. Udono, H., and P.K. Srivastava. 1993. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178:1391-1396.
8. Ullrich, S.J., E.A. Robinson, L.W. Law, M. Willingham, and E.A. Appela. 1986. Mouse tumor-specific antigen is a heat shock-related protein. Proc. Natl. Acad. Sci. USA. 83:3121-3125.
9. Tamura, Y., P. Peng, K. Liu, M. Daou, and P.K. Srivastava. 1997. Immunotherapy of metastatic lung cancer by heat shock protein preparations. Science. 278:117-120.
10. Tiwari, R.K., G. Li, M.P. Osborne, M. Daou, and P.K. Srivastava. 1996. Cancer derived heat shock protein, gp96, elicits protective immunity in a prostate cancer model. Proc. Am. Assoc. Cancer. Res. 37:3240. (Abstr.)
11. Janetzki, S., N.E. Blachere, and P.K. Srivastava. 1998. Generation of tumor-specific CTLs and memory T cells by vaccination with tumor-derived heat shock protein preparation. J. Immumother. 21:269-276.
12. Heikema, A., E. Agsteribbe, J. Wilschut, and A. Huckriede. 1997. Generation of heat shock protein-based vaccines by loading of gp96 with antigenic peptides. Immunol. Lett. 57: 69-74.
13. Blachere, N.E., H. Udono, S. Janetzki, Z. Li, M. Heike, and P.K. Srivastava. 1993. Heat shock protein vaccines against cancer. J. Immunother. 14:352-356.
14. Suto, R., and P.K. Srivastava. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 269:1585-1588.
15. Ciupitu, A.M., M. Petersson, C.L. O'Donnell, K. Williams, S. Jindal, R. Kiessling, and R.M. Welsh. 1998. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187:685-691.
16. Arnold, D., S. Faath, H.G. Ramensee, and H. Schild. 1995. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182:885-889.
17. Srivastava, P.K. 1993. Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv. Cancer Res. 62:153-177.
18. North, R.J., and I. Bursuker. 1984. Generation and decay of the immune response to a progressive fibrosarcoma. J. Exp. Med. 159:1295-1311.
19. + T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int. J. Cancer. 55:338-343.
20. + T lymphocytes to mediate protective immunity against Leishmania. J. Exp. Med. 159:1819-1827.
21. + T cells. J. Clin. Invest. 94:797-807.
22. Srivastava, P.K., H. Udono, N.E. Blachere, and Z. Li. 1994. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 39:93-98.
23. Mitchison, N.A. 1968. The dosage requirements for immunological paralysis by soluble proteins. Immunology. 15:509-530.
24. Brichard, V.G., G. Warnier, A. Van Pel, G. Morlighem, S. Lucas, and T. Boon. 1995. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur. J. Immunol. 25:664-671.